WO2026033458 - DOSES AND PHARMACEUTICAL COMPOSITIONS OF A CD33 X Vδ2 BISPECIFIC ANTIBODY FOR THE TREATMENT OF CANCER
National phase entry is expected:
Publication Number
WO/2026/033458
Publication Date
12.02.2026
International Application No.
PCT/IB2025/058046
International Filing Date
07.08.2025
Title **
[English]
DOSES AND PHARMACEUTICAL COMPOSITIONS OF A CD33 X Vδ2 BISPECIFIC ANTIBODY FOR THE TREATMENT OF CANCER
[French]
DOSES ET COMPOSITIONS PHARMACEUTIQUES D'UN ANTICORPS BISPÉCIFIQUE CD33 X VΔ2 POUR LE TRAITEMENT DU CANCER
Applicants **
JANSSEN BIOTECH, INC.
Inventors
DASH, Ranjeet Prasad
MCNAUGHTON, Brian Richard
RAMAN, Kavita
SHAH, Nirav Raju
GUTTKE, Christina Diane
SAFER, Karim
KALLAL, Lorena A
ELASHKAR, Sara Mohamed A
BRADFORD, Kathryn Lee
Priority Data
63/680,866
08.08.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3120 | |
| EPO | Filing, Examination, Granting | 22339 | |
| Japan | Filing, Examination, Granting | 2927 | |
| South Korea | Filing, Examination, Granting | 3643 | |
| USA | Filing, Examination, Granting | 12340 |
Total:
44,369
Contact Us
Abstract[English]
The present disclosure relates to doses and dosing regimens of a bispecific antibody that binds myeloid cell surface antigen CD33, and the Vδ2 chain of the human Vγ9Vδ2 T cell receptor; to pharmaceutical compositions comprising said antibodies, as well as methods of administration of the referred doses, and to the use of said antibodies in the treatment of Acute Myeloid Leukemia (AML) or Myelodysplastic Neoplasms (MDS), in particular Relapsed or Refractory (R/R) AML or MDS.[French]
La présente divulgation concerne des doses et des schémas posologiques d'un anticorps bispécifique qui se lie à l'antigène CD33 de surface des cellules myéloïdes, et la chaîne Vδ2 du récepteur des lymphocytes T Vγ9Vδ2 humain ; des compositions pharmaceutiques comprenant lesdits anticorps, ainsi que des méthodes d'administration des doses mentionnées, et l'utilisation desdits anticorps dans le traitement de la leucémie myéloïde aiguë (AML) ou des néoplasmes myélodysplasiques (MDS), en particulier de l'AML ou du MDS récidivant ou réfractaire (R/R).